Ticagrelor for the treatment of arterial thrombosis

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 13, 2010, Pages 2251-2259

  Gurbel, Paul A ^a   Kereiakes, Dean J ^b   Tantry, Udaya S ^a  

^a SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

^b The Carl & Edyth Lindner Center for Research & Education   (United States)

Author keywords

Acute coronary syndromes; Clopidogrel; Platelets; Ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYTOCHROME P450; PLACEBO; PRASUGREL; PURINERGIC P2Y RECEPTOR; TICAGRELOR;

ARTERY THROMBOSIS; BLEEDING; BODY MASS; CARDIOLOGY; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; INTESTINE ABSORPTION; KIDNEY FUNCTION; MEDLINE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STROKE;

ADENOSINE; ARTERIES; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; HUMANS; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; THROMBOSIS; TREATMENT OUTCOME;

EID: 77955787259     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.511175     Document Type: Review

References (31)

1. Braunwald E, Angiolillo D, Bates E, et al. Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes. Clin Cardiol 2008;31(3 Suppl 1):I2-9
2. Murugappa S, Kunapuli SP. The role of ADP receptors in platelet function. Front Biosci 2006;11:1977-1986
3. Gachet C. P2 receptors, platelet function and pharmacological implications. Thromb Haemost 2008;99:466-472
4. Gawaz M, Favaloro EJ. Platelets, inflammation and cardiovascular diseases. New concepts and therapeutic implications. Semin Thromb Hemost 2010;36:129-130
5. Gurbel PA, Bliden KP, Guyer K, et al. Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting. Thromb Res 2007;119:563-570
6. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to ADP. J Am Coll Cardiol 2010; In press
7. Gurbel PA, Tantry US. The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome. J Interv Cardiol 2008;21(Suppl 1):S10-17
8. Reinhart KM, White CM, Baker WL. Prasugrel: a critical comparison with clopidogrel. Pharmacotherapy 2009;29:1441-1451
9. Wiviott SD, Braunwald E, McCabe CH, et al.; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015
10. Husted S, van Giezen JJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther 2009;27:259-274
11. van Giezen JJ, Berntsson P, Zachrisson H, Bjorkman JA. Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis. Thromb Res 2009;124:565-571
12. Van Giezen JJ, Berntsson P, Nilsson L, Wissing BM. Direct oral P2Y12 receptor antagonist AZD6140 potently and reversibly binds to the rh-P2Y12 receptor expressed on CHO-K1 cells [abstract P207]. Arterioscler Thromb Vasc Biol 2008;28:e-72
13. Van Giezen JJ, Nilsson L, Berntsson P, et al. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost 2009;7:1556-1565
14. Peters G, Robbie G. Single dose pharmacokinetics and pharmacodynamics of AZD6140. Haematologica 2004;89(Suppl 7):14-15
15. Butler K, Teng R. AZD6140, the first reversible oral platelet P2Y12 receptor antagonist, exhibits linear pharmacokinetics following multiple doses in healthy subjects, with greater and less variable inhibition of platelet aggregation compared with clopidogrel [abstract 562]. Can J Clin Pharmacol 2008;15:e684-5
16. Peters GR, Butler KA, Winter HR. Multiple-dose pharmacokinetics (PK) and pharmacodynamics (PD) of the oral reversible, orally active ADP receptor antagonist AZD6140. Eur Heart J 2006;27(Suppl 1):P4556
17. Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006;27:1038-1047
18. Cannon CP, Husted S, Harrington RA, et al.; for the DISPERSE-2 Investigators. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of theDISPERSE-2 trial. J Am Coll Cardiol 2007;50:1844-1851
19. Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007;50:1852-1856
20. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057
21. Schomig A. Ticagrelor-is there need for a new player in the antiplatelet-therapy field? N Engl J Med 2009;361:1108-1111
22. Cannon CP, Harrington RA, James S, et al.; PLATelet inhibition and patient Outcomes Investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasivestrategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010;375:283-293
23. Held C, Bassand J-P, Becker RC, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery; results from the PLATO trial. Presented at American College of Cardiology Meetings; March 14-16, 2010; Atlanta
24. Steg G, Stefen J, Harrington RA, et al. PLATO STEMI: outcomes in patients with STEMI and planned PCI. Presented at American Heart Association Meetings; November 14-17, 2009; Orlando.
25. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009;120:2577-2585
26. Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 2010;121:1188-1199
27. Storey RF, Bliden KP, Patil SB, et al. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel or placebo in the ONSET/OFFSET study. J Am Coll Cardiol 2010;56:185-193
28. Husted SE, Gurbel PA, Bliden KP, et al. Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery diseases. Presented at American Heart Association Meetings; November 14-17, 2009; Orlando.
29. Hamm CW. Bleeding management and pharmacological strategy in primary percutaneous coronary intervention. Eur Heart J 2009;11:C9-12
30. Bjorkman JA, Kirk I, van Giezen JJJ. AZD6140 inhibits adenosine uptake into erythrocytes and enhances coronary blood flow after local ischemia or intracoronary adenosine infusion [abstract 245]. Circulation 2007;116(Suppl):II-28
31. Forman MB, Stone GW, Jackson EK. Role of adenosine as adjunctive therapy in acute myocardial infarction. Cardiovasc Drug Rev 2006;24:116-147